HSCT recipient demographics, engraftment, GVHD, and NK/NK ligand genotyping
| Subject no. . | Age (y) . | Donor . | aGVHD . | Affected organs . | CD34 dose (×106/kg) . | CD3 dose (×104/kg) . | NK dose (×105/kg) . | Day of aNK-DLI . | Day of GVHD diagnosis . | % Donor CD3 chimerism . | KIR–ligand mismatch . | Donor haplotype . | . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 14 . | Day 28 . | Recipient HLA . | ||||||||||||
| 1 | 34.5 | MUD | Grade 4 | Stage 4 skin; stage 3 GI, ocular involvement | 7.54 | 2 | 1 | 24 | 25 | 73 | 100 | (KIR2DL1/C2) | A/A | 03, 26 |
| 2 | 33.4 | MSD | None | — | 3.72 | 1.1 | 1 | 14 | NA | — | 8 | None | B/x KIR2DS2-3 | 26, 31 |
| 3 | 22.1 | MUD | Grade 2 | Stage 2 skin; stage 1 GI | 6.8 | 1.4 | 1 | 9 | 30 | 96 | 100 | (KIR2DL1/C2) | A/A | 29, 32 |
| 4 | 16.8 | MUD | Grade 4 | Stage 3 skin; stage 3 GI | 3.46 | 1.4 | 1 | 9, 34 | 12, 38* | 100 | 100 | None | A/A KIR2DS4 | 11, 33 |
| 5 | 24.2 | MSD | None | — | 5.44 | 1.4 | 1 | 8, 35 | NA | 2 | 38 | None | B/x KIR2DS2-4 | 31, 68 |
| 6 | 18.7 | MSD | None | — | 7.26 | 1.4 | 1 | 8, 36 | NA | 36 | 92 | (KIR2DL1/C2) | B/x KIR3DS1; KIR2DS1-5 | 01, 02 |
| 7 | 14.4 | MSD | None | — | 7.94 | 1.4 | 1 | 8, 35 | NA | 7 | 78 | None | A/A KIR2DS4 | 02, 24 |
| 8 | 15.8 | MUD | Grade 4 | Stage 4 skin, stage 3 GI | 6.27 | 1.4 | 1 | 9 | 13 | 98 | 92 | (KIR3DL1/Bw4) | B/x KIR2DS4; KIR2DS2 | 11, 31 |
| 9 | 21.2 | MSD | Nongradable† | Liver, biopsy-proven | 7.93 | 1.4 | 10 | 21 | 48 | 73 | 27 | (KIR2DL3/C1) | A/A | 01, 29 |
| Subject no. . | Age (y) . | Donor . | aGVHD . | Affected organs . | CD34 dose (×106/kg) . | CD3 dose (×104/kg) . | NK dose (×105/kg) . | Day of aNK-DLI . | Day of GVHD diagnosis . | % Donor CD3 chimerism . | KIR–ligand mismatch . | Donor haplotype . | . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 14 . | Day 28 . | Recipient HLA . | ||||||||||||
| 1 | 34.5 | MUD | Grade 4 | Stage 4 skin; stage 3 GI, ocular involvement | 7.54 | 2 | 1 | 24 | 25 | 73 | 100 | (KIR2DL1/C2) | A/A | 03, 26 |
| 2 | 33.4 | MSD | None | — | 3.72 | 1.1 | 1 | 14 | NA | — | 8 | None | B/x KIR2DS2-3 | 26, 31 |
| 3 | 22.1 | MUD | Grade 2 | Stage 2 skin; stage 1 GI | 6.8 | 1.4 | 1 | 9 | 30 | 96 | 100 | (KIR2DL1/C2) | A/A | 29, 32 |
| 4 | 16.8 | MUD | Grade 4 | Stage 3 skin; stage 3 GI | 3.46 | 1.4 | 1 | 9, 34 | 12, 38* | 100 | 100 | None | A/A KIR2DS4 | 11, 33 |
| 5 | 24.2 | MSD | None | — | 5.44 | 1.4 | 1 | 8, 35 | NA | 2 | 38 | None | B/x KIR2DS2-4 | 31, 68 |
| 6 | 18.7 | MSD | None | — | 7.26 | 1.4 | 1 | 8, 36 | NA | 36 | 92 | (KIR2DL1/C2) | B/x KIR3DS1; KIR2DS1-5 | 01, 02 |
| 7 | 14.4 | MSD | None | — | 7.94 | 1.4 | 1 | 8, 35 | NA | 7 | 78 | None | A/A KIR2DS4 | 02, 24 |
| 8 | 15.8 | MUD | Grade 4 | Stage 4 skin, stage 3 GI | 6.27 | 1.4 | 1 | 9 | 13 | 98 | 92 | (KIR3DL1/Bw4) | B/x KIR2DS4; KIR2DS2 | 11, 31 |
| 9 | 21.2 | MSD | Nongradable† | Liver, biopsy-proven | 7.93 | 1.4 | 10 | 21 | 48 | 73 | 27 | (KIR2DL3/C1) | A/A | 01, 29 |
Gray rows highlight patients who developed aGVHD, MUD = 10/10 matched unrelated donors, MSD = 6/6 matched sibling donors.
GI, gastrointestinal; NA, not available.
Day of GVHD diagnosis following second aNK-DLI.
GVHD was demonstrated on liver biopsy, but because bilirubin was not elevated, the standard criteria used to grade GVHD could not be used.